Folate pathway modulation

The term "Folate pathway modulation" refers broadly to therapeutic strategies that alter the activity of components within the cellular pathways responsible for processing and utilizing **folic acid**. This includes targeting enzymes essential for one-carbon transfer reactions required for DNA/RNA synthesis and methylation processes critical for gene expression regulation. Modulation can also involve targeting membrane proteins responsible for transporting or binding extracellular folates—most notably **folate receptors** such as FRα—which are overexpressed on certain tumor cells including ovarian cancer, making them attractive candidates for targeted drug delivery using antibody-drug conjugates or small-molecule conjugates. Drugs that modulate this pathway are used primarily in oncology but also have roles in treating autoimmune diseases by affecting immune cell proliferation. However, because these pathways are fundamental to normal cellular function—especially during development—therapeutic intervention carries risks including cytopenias, mucositis, organ toxicities, and teratogenic effects.

Other names

Folate metabolismOne-carbon metabolismFolic acid pathwayAntifolate therapy (context-dependent)

Depending on drug class—Inhibition of key enzymes in the folate cycle such as dihydrofolate reductase or thymidylate synthase by antifolates blocks DNA synthesis/proliferation in rapidly dividing cells. Targeted delivery via conjugation to drugs that bind cell-surface receptors like FRα for selective uptake into cancer cells ("Trojan Horse" mechanism).